This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Drug Names(s): HPV 16/18 L1 VLP Vaccine (AS04), GSK-580299
Description: Cervarix is a vaccine protecting against infection with human papillomavirus serotypes 16 and 18, which are causatively linked to cervical cancer. It is also the first US-approved vaccine containing the Corixa/GSK proprietary adjuvant AS04, a combination of the lipopolysaccharide analog monophosphoryl lipid A (MPL) and alum. Cervarix is approved in the US for the prophylaxis of HPV infection in feamles age 10-25 years.
In December 1997, MedImmune entered into an exclusive license agreement with GSK for certain patents and know-how that have formed the basis for the development of Cervarix. MedImmune then amended its agreement with GSK to allow Merck to sublicense rights to its patents as it relates to Gardasil.
MedImmune will receive certain milestone payments and royalties on future development and sales of both Cervarix and Gardasil. GSK will also receive a royalty on sales of Gardasil.
In June 2007, AstraZeneca closed its acquisition of MedImmune.
In 1995 CSL entered into an exclusive License Agreement with Merck for certain patents and know-how related to HPV which had been previously licensed by CSL from the University of Queensland as a result of a research collaboration undertaken between them. This collaboration formed the basis for the development by Merck of Gardasil. CSL will receive royalties from Merck for an extended period.
In February...See full deal structure in Biomedtracker
Partners: AstraZeneca PLC CSL Limited
Additional information available to subscribers only: